Literature DB >> 9393573

Lung carcinomas composed of rhabdoid cells.

R Chetty1, B Bhana, S Batitang, D Govender.   

Abstract

Rhabdoid tumours form a distinctive morphological entity that is associated with aggressive biological behaviour. They have been described in several sites and tumour types. This paper presents three new cases of rhabdoid lung cancers. Lung cancers were analysed for the presence of cells with the rhabdoid phenotype: eccentric vesicular nuclei and abundant eosinophilic cytoplasm. Cells displaying this morphology were then subjected to immunohistochemistry and electron microscopy. The relevant clinical data on these cases were then accessed. Three cases conforming to the morphological, immunophenotypic and ultrastructural characteristics of rhabdoid cells were identified. Two of the cases were associated with foci of adenocarcinoma and the remaining case was a large cell neuroendocrine carcinoma. Two of the cases showed rapid clinical courses with the patients dying of disease within 6 months. Lung tumours with a rhabdoid phenotype are uncommon but are noteworthy because of their aggressive behaviour and, hence, poor prognosis.

Entities:  

Mesh:

Year:  1997        PMID: 9393573     DOI: 10.1016/s0748-7983(97)93725-2

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

Review 1.  [Lung cancer. Developments, concepts and preview of the new WHO classification].

Authors:  I Petersen; A Warth
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  Lung cancer: developments, concepts, and specific aspects of the new WHO classification.

Authors:  Iver Petersen; Arne Warth
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-22       Impact factor: 4.553

Review 3.  Neuroendocrine tumor of the pancreas with rhabdoid feature.

Authors:  Tetsuyuki Miyazaki; Shinichi Aishima; Minoru Fujino; Keigo Ozono; Yuichiro Kubo; Yasuhiro Ushijima; Takashi Osoegawa; Eikichi Ihara; Itou Tetsuhide; Takao Ohtsuka; Masafumi Nakamura; Yoshinao Oda
Journal:  Virchows Arch       Date:  2018-06-24       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.